Loading clinical trials...

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors | Clinical Trials | Clareo Health

UNKNOWNPHASE3

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

NCT01373736•Vancouver Coastal Health

Summary

The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects must have a clinical indication for 123I-MIBG imaging to evaluate for the presence, extent, or status of neuroendocrine tumors;
•subjects must be able and willing to comply with study procedures.

Exclusion Criteria

•Subjects with history of renal insufficiency (serum creatinine level \> 3.0 mg/dL \[265 µmol/L\]) and inability to be withdrawn from medications known to interfere with 123I-MIBG uptake;
•Subjects unable to tolerate lying supine;
•Subjects pregnant or breastfeeding, unless the information to be gained outweighs the possible hazardous effects of 123I-MIBG administration. Where the assessment of the risk/benefit ration suggests the use of 123I-MIBG in nursing mothers, the breastfeeding should be discontinued for at least 48 hours post-injection.

Locations (1)

Vancouver Coastal Health

Vancouver, British Columbia, Canada

Key Dates

Last Updated

June 15, 2011

Conditions

PheochromocytomaNeuroblastomaParagangliomaMedullary Thyroid CarcinomaCarcinoid Tumors

Interventions

123I-meta-iodobenzylguanidine

DRUG

Contacts

Daniel Worsley, MD

CONTACT

604-875-4629 worsley@triumf.ca

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

NCT04936529

Neuroblastoma

View study

RECRUITINGPHASE1/PHASE2

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

NCT06541262

NeuroblastomaEwing Sarcoma+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2011Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors

Inclusion Criteria

Exclusion Criteria

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow

Familial Investigations of Childhood Cancer Predisposition